Join
Live feed
·
INSIDERFilingvia Quantisnow
Revance Therapeutics Inc. logo

CMO & Global Therapeutics Lead Hollander David sold $16,296 worth of shares (3,908 units at $4.17), decreasing direct ownership by 4% to 104,945 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
RVNC· Revance Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RVNC (Revance Therapeutics Inc.) and more on Quantisnow.